首页> 美国卫生研究院文献>Clinical and Translational Science >Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi‐Ethnic Allele and Copy Number Variant Detection
【2h】

Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi‐Ethnic Allele and Copy Number Variant Detection

机译:29基因临床药源性基因分型面板的开发和分析验证:多民族等位基因和拷贝数变体检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To develop a novel pharmacogenetic genotyping panel, a multidisciplinary team evaluated available evidence and selected 29 genes implicated in interindividual drug response variability, including 130 sequence variants and additional copy number variants (CNVs). Of the 29 genes, 11 had guidelines published by the Clinical Pharmacogenetics Implementation Consortium. Targeted genotyping and CNV interrogation were accomplished by multiplex single‐base extension using the MassARRAY platform (Agena Biosciences) and multiplex ligation‐dependent probe amplification (MRC Holland), respectively. Analytical validation of the panel was accomplished by a strategic combination of > 500 independent tests performed on 170 unique reference material DNA samples, which included sequence variant and CNV accuracy, reproducibility, and specimen (blood, saliva, and buccal swab) controls. Among the accuracy controls were 32 samples from the 1000 Genomes Project that were selected based on their enrichment of sequence variants included in the pharmacogenetic panel (VarCover.org). Coupled with publicly available samples from the Genetic Testing Reference Materials Coordination Program (GeT‐RM), accuracy validation material was available for the majority (77%) of interrogated sequence variants (100% with average allele frequencies > 0.1%), as well as additional structural alleles with unique copy number signatures (e.g., CYP2D6*5, *13, *36, *68; CYP2B6*29; and CYP2C19*36). Accuracy and reproducibility for both genotyping and copy number were > 99.9%, indicating that the optimized panel platforms were precise and robust. Importantly, multi‐ethnic allele frequencies of the interrogated variants indicate that the vast majority of the general population carries at least one of these clinically relevant pharmacogenetic variants, supporting the implementation of this panel for pharmacogenetic research and/or clinical implementation programs.
机译:为了开发一种新型药物发生基因分型面板,多学科团队评估可用证据,并选择了29个基因,涉及用于中的细胞药物反应变异性,包括130个序列变体和额外的拷贝数变体(CNV)。在29个基因中,11名临床药科学实施联盟发表了指南。通过使用MassArray平台(Agena Biosciences)和多重连接依赖性探针扩增(MRC Holland),通过多路复用单碱基延伸来完成靶向基因分型和CNV询问。面板的分析验证是通过在170个独特的参考材料DNA样品上进行的> 500个独立测试的战略组合来实现,该方法包括序列变异和CNV精度,再现性和标本(血液,唾液和颊拭子)对照。在精度对照中,来自1000个基因组项目的32个样品,该项目是根据其富集药物植物(Varcover.org)中包含的序列变体的富集选择。再加上来自遗传检测参考资料协调计划(GET-RM)的公开样品,可用于大多数(77%)的询问序列变体(100%,平均等位基因频率> 0.1%)提供精度验证材料(100%),以及具有唯一拷贝数签名的附加结构等位基因(例如,CYP2D6 * 5,* 13,* 36,* 68; CYP2B6 * 29;和CYP2C19 * 36)。基因分型和拷贝数的准确性和再现性为99.9%,表明优化的面板平台精确且稳健。重要的是,询问变体的多族裔等位基因频率表明绝大多数一般人群携带这些临床相关的药物发生变种中的至少一个,支持该小组的药物发生研究和/或临床实施方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号